Item 2. Properties
Item 2. PROPERTIES
As of December 31, 2024, we owned or leased approximately 160 properties. The locations and primary functions of significant properties are summarized in the following tables:
U.S. Location: Manufacturing Administrative R&D Sales & marketing Warehouse Distribution center
Thousand Oaks, CA (1)
x
x
x
x
x
x
Juncos, Puerto Rico x
x
x
x
West Greenwich, RI x
x
x
Deerfield, IL
x
x
x
Cambridge, MA x
New Albany, OH
x
x
x
San Francisco, CA x
Tampa, FL x
x
Louisville, KY x
x
Other U.S. cities (2)
x
x
x
ROW Location: Manufacturing Administrative R&D Sales & marketing Warehouse Distribution center
Brazil x
x
Canada x
x
x
China x
x
Denmark x
x
x
Germany x x x
Iceland x x
India
x
Ireland x
x
x
x
x
Netherlands x
x
x
x
x
Singapore x
x
x
x
United Kingdom x
x
x
Other countries (2)
x
x
x
x
____________
(1) Corporate headquarters
(2) Includes smaller properties in other U.S. and ROW locations, primarily for administrative and sales & marketing
Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. Additionally, in 2024 we received FDA licensure of our manufacturing facility in New Albany, Ohio; opened a new technology and innovation site in India; and continued to progress on the construction of our first drug substance manufacturing facility in Holly Springs, North Carolina. Furthermore, in January 2025, we broke ground on our second drug substance manufacturing facility in Holly Springs, North Carolina. There are no material encumbrances on our owned properties.
We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item 1A. Risk Factors for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.
See Item 1. Business—Manufacturing, Distribution and Raw Materials.
57
Item 3. LEGAL PROCEEDINGS
Certain of the legal proceedings in which we are involved are discussed in Part IV—Note 20, Contingencies and commitments, to the Consolidated Financial Statements and are hereby incorporated by reference.
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
58
PART II
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.